Article
Genotype analysis of rotaviruses isolated from children during a phase III clinical trial with the hexavalent rotavirus vaccine in China.
Virologica Sinica - 1 Dec 2023
Zou Wenqi, Yu Qingchuan, Liu Yan, Li Qingliang, Chen Hong, Gao Jiamei, Shi Chen, Wang Ying, Chen Wei, Bai Xuan, Yang Biao, Zhang Jiuwei, Dong Ben, Ruan Bo, Zhou Liuyifan, Xu Gelin, Hu Zhongyu, Yang Xiaoming
Abstract excerpt
The oral hexavalent live human-bovine reassortant rotavirus vaccine (RV6) developed by Wuhan Institute of Biological Products Co., Ltd (WIBP) has finished a randomized, placebo-controlled phase III clinical trial in four provinces of China in 2021. The trail demonstrated that RV6 has a high vaccine efficacy against the prevalent strains and is safe for use in infants. During the phase III clinical trial...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.